-DOCSTART- -X- O
The -X- _ O
leishmaniases -X- _ O
are -X- _ O
a -X- _ O
complex -X- _ O
of -X- _ O
vector-borne -X- _ O
diseases -X- _ O
caused -X- _ O
by -X- _ O
protozoan -X- _ O
parasites -X- _ O
of -X- _ O
the -X- _ O
genus -X- _ O
Leishmania. -X- _ O
LEISHDNAVAX -X- _ B-Intervention
is -X- _ O
a -X- _ O
multi-antigen -X- _ B-Intervention
, -X- _ I-Intervention
T-cell -X- _ I-Intervention
epitope-enriched -X- _ I-Intervention
DNA -X- _ I-Intervention
vaccine -X- _ I-Intervention
candidate -X- _ I-Intervention
against -X- _ I-Intervention
human -X- _ I-Intervention
leishmaniasis. -X- _ I-Intervention
The -X- _ O
vaccine -X- _ O
candidate -X- _ O
has -X- _ O
been -X- _ O
proven -X- _ O
immunogenic -X- _ O
and -X- _ O
showed -X- _ O
prophylactic -X- _ O
efficacy -X- _ O
in -X- _ O
preclinical -X- _ O
studies. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
describe -X- _ O
the -X- _ O
safety -X- _ O
testing -X- _ O
of -X- _ O
LEISHDNAVAX -X- _ B-Intervention
in -X- _ O
naive -X- _ O
mice -X- _ O
and -X- _ O
rats -X- _ O
, -X- _ O
complemented -X- _ O
by -X- _ O
the -X- _ O
demonstration -X- _ O
of -X- _ O
tolerability -X- _ O
in -X- _ O
Leishmania-infected -X- _ B-Patient
mice. -X- _ I-Patient
Biodistribution -X- _ O
and -X- _ O
persistence -X- _ O
were -X- _ O
examined -X- _ O
following -X- _ O
single -X- _ B-Outcome
and -X- _ I-Outcome
repeated -X- _ I-Outcome
intradermal -X- _ I-Outcome
( -X- _ I-Outcome
i.d. -X- _ I-Outcome
) -X- _ I-Outcome
administration -X- _ I-Outcome
to -X- _ I-Outcome
rats. -X- _ I-Outcome
DNA -X- _ B-Outcome
vectors -X- _ I-Outcome
were -X- _ I-Outcome
distributed -X- _ I-Outcome
systemically -X- _ I-Outcome
but -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
accumulate -X- _ I-Outcome
upon -X- _ I-Outcome
repeated -X- _ I-Outcome
injections. -X- _ I-Outcome
Although -X- _ O
vector -X- _ O
DNA -X- _ O
was -X- _ O
cleared -X- _ O
from -X- _ O
most -X- _ O
other -X- _ O
tissues -X- _ O
within -X- _ O
60 -X- _ O
days -X- _ O
after -X- _ O
the -X- _ O
last -X- _ O
injection -X- _ O
, -X- _ O
it -X- _ O
persisted -X- _ O
in -X- _ O
skin -X- _ O
at -X- _ O
the -X- _ O
site -X- _ O
of -X- _ O
injection -X- _ O
and -X- _ O
in -X- _ O
draining -X- _ O
lymph -X- _ O
nodes. -X- _ O
Evaluation -X- _ B-Outcome
of -X- _ I-Outcome
single-dose -X- _ I-Outcome
and -X- _ I-Outcome
repeated-dose -X- _ I-Outcome
toxicity -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
vaccine -X- _ I-Outcome
candidate -X- _ I-Outcome
after -X- _ I-Outcome
i.d. -X- _ I-Outcome
administration -X- _ I-Outcome
to -X- _ I-Outcome
naive -X- _ I-Outcome
, -X- _ I-Outcome
non-infected -X- _ I-Outcome
mice -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
reveal -X- _ I-Outcome
any -X- _ I-Outcome
safety -X- _ I-Outcome
concerns. -X- _ I-Outcome
LEISHDNAVAX -X- _ B-Outcome
was -X- _ I-Outcome
also -X- _ I-Outcome
well -X- _ I-Outcome
tolerated -X- _ I-Outcome
in -X- _ I-Outcome
Leishmania-infected -X- _ I-Outcome
mice. -X- _ I-Outcome
Taken -X- _ O
together -X- _ O
, -X- _ O
our -X- _ O
results -X- _ O
substantiate -X- _ O
a -X- _ O
favorable -X- _ O
safety -X- _ O
profile -X- _ O
of -X- _ O
LEISHDNAVAX -X- _ B-Intervention
in -X- _ O
both -X- _ O
naive -X- _ O
and -X- _ O
infected -X- _ O
animals -X- _ O
and -X- _ O
thus -X- _ O
, -X- _ O
support -X- _ O
the -X- _ O
initiation -X- _ O
of -X- _ O
clinical -X- _ O
trials -X- _ O
for -X- _ O
both -X- _ O
preventive -X- _ O
and -X- _ O
therapeutic -X- _ O
applications -X- _ O
of -X- _ O
the -X- _ O
vaccine -X- _ O
. -X- _ O

